株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

第3回眼科論争国際会議(2012年):閉会後のレビューと分析

3rd World Congress on Controversies in Ophthalmology 2012 - Post-Conference Review and Analysis

発行 GlobalData 商品コード 235473
出版日 ページ情報 英文 16 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
第3回眼科論争国際会議(2012年):閉会後のレビューと分析 3rd World Congress on Controversies in Ophthalmology 2012 - Post-Conference Review and Analysis
出版日: 2012年03月27日 ページ情報: 英文 16 Pages
概要

当レポートでは、2012年3月22〜25日にトルコ・イスタンブールで開催された、3rd World Congress on Controversies in Ophthalmology(第3回眼科論争国際会議)の報告内容に関するレビューと分析とをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 報告ハイライト

  • 糖尿病性黄班浮腫に伴う、黄斑・網膜神経線維層に対する、硝子体内トリアムシノロンアセトニドおよびベバシズマブの効果の比較
  • 新生血管の加齢性黄班変種の患者における、硝子体内ラニズマブを用いた治療でのコンプライアンス
  • 急性中心性漿液性脈絡網膜症における、硝子体内へのラニビズマブの注入と眼底自発蛍光の変化の効果
  • 緑内障の治療目標としての角膜ヒステレシス
  • アデノウイルス角結膜炎より派生した上皮下浸潤の治療用の0.05%局所シクロスポリン
  • 前部ぶどう膜炎関連の強直性脊椎炎の再発防止に際しての、スルファサラジンの取り扱い
  • 加齢性黄班変種における、ラニビズマフの注入頻度と視覚的効果
  • 脈絡膜新生血管膜に対する、光力学的療法と硝子体内ラニズマブ(IVR)療法の組み合わせと、IVR療法単独との比較
  • 増殖性糖尿病性網膜症の管理における、硝子体内VEGF阻害薬と迅速散布レーザーとの併用
  • 過去の硝子体内注入にはでは直りにくかった、びまん性糖尿病性黄班浮腫に対する、ベバシズマブとトリアムシノロンの併用治療の効果
  • 水晶体乳化による白内障手術後の眼圧に対する、合剤治療(1%ブリンゾラミドと0.5%チモロール)の効果
  • 網膜静脈閉塞症に伴う黄班浮腫の治療で、2種類以上のOzurdexの注入を受けた患者の、遡及データ収集研究
  • チモロール・ドルゾラミド合剤では適切に管理できなかった患者へのラタノプロストによる、追加的な眼圧減少効果
  • 略語集
  • 免責事項

図表一覧

目次

Abstract

3rd World Congress on Controversies in Ophthalmology 2012 - Post-Conference Review and Analysis

Summary

GlobalData, the industry analysis specialist, has released its new conference alerts, "3rd World Congress on Controversies in Ophthalmology 2012 - Post-Conference Review and Analysis". The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.

The annual symposium of the 3rd World Congress on Controversies in Ophthalmology (COPHy) was held in Istanbul, Turkey from March 22 to 25, 2012. The four-day conference included discussions among chairpersons, speakers and the audience, who examined and presented poster presentations related to the most relevant issues that were raised during the course of 2011 within the field of ophthalmology. This report aims to cover some of the scientific presentations and articles released during the conference.

Scope

The report provides complete coverage of conference. Its scope includes -

  • Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
  • review of pre- and post-conference KOL/analyst comments
  • Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.

Reasons to buy

The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -

  • Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
  • Explore M&A opportunities by identifying key products and market players.
  • Develop market-entry and market expansion strategies.
  • Identify key players best positioned to take advantage of the market opportunities.
  • Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 3

2 3rd World Congress on Controversies in Ophthalmology - Post-Conference Highlights 4

  • 2.1 Comparison of Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab on Macular and Retinal Nerve Fiber Layer Thickness with Diabetic Macular Edema 4
  • 2.2 Compliance to Treatment with Intravitreal Ranizumab in Patients with Neovascular Age-Related Macular Degeneration 5
  • 2.3 Efficacy of Intravitreal Ranibizumab Injection and Fundus Autofluorescence Changes in Acute Central Serous Chorioretinopathy 5
  • 2.4 Corneal Hysteresis as a Therapeutic Target in Glaucoma 6
  • 2.5 Topical Cyclosporine 0.05 % for the Treatment of Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis 7
  • 2.6 Sulfasalazine Treatment in Preventing Recurrences of Anterior Uveitis Associated Ankylosing Spondylitis 8
  • 2.7 Ranibizumab Injection Frequency and Visual Outcome in Age-Related Macular Degeneration 9
  • 2.8 Comparing Combination of Photodynamic Therapy and Intravitreal Ranizumab Therapy with IVR Monotherapy on Choroidal Neovascular Membranes 9
  • 2.9 Combined Intravitreal Anti-VEGF with Prompt Scatter Laser in the Management of Proliferative Diabetic Retinopathy 11
  • 2.10 The Effect of Combined Treatment with Bevacizumab and Triamcinolone for Diffuse Diabetic Macular Edema Refractory to Previous Intravitreal Injections 12
  • 2.11 Effect of Brinzolamide 1% and Timolol 0.5% Fixed Combination on Intraocular Pressure after Cataract Surgery with Phacoemulsification 13
  • 2.12 Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex Injections for Macular Edema Secondary to Retinal Vein Occlusion 13
  • 2.13 Additive Intraocular Pressure Reducing the Effect of Latanoprost in Patients Insufficiently Controlled on Timolol-Dorzolamide Fixed Combination 14
  • 2.14 Abbreviations 15
  • 2.15 Disclaimer 16

List of Tables

1.1 List of Tables

  • Table 1: Effect of Intravitreal Triamcinolone Acetonide and Bevacizumab on Diabetic Macular Edema Patients 4
  • Table 2: Efficacy Results for Intravitreal Ranibizumab Injection and Fundus Autofluorescence Changes in Acute Central Serous Chorioretinopathy 6
  • Table 3: Yearly Attack Frequency of Anterior Uveitis Before and After Sulfasalazine Treatment 8
  • Table 4: Effect of Combination of Photodynamic Therapy and IVR vs IVR Monotherapy on Patients with CNVM 10
  • Table 5: Effect on OCT Macula Thickness of Combination of PDT and IVR with IVR Monotherapy on CNVM 10
  • Table 6: Change in BCVA in Patients for a Mean Reinjection Time Receiving Two or More Ozurdex Injections for Macular Edema Secondary to RVO 14
Back to Top